Further, miR-200b could target transcription factors, AP-2 alpha (TFAP2A), and MAPK7, which, in turn, inhibit the expression of TGF-β, impair TGF-β-induced EMT and decrease cancer cell proliferation in vitro. Here, TFAP2A is linked to cancer.